Skip to main content

Advertisement

SpringerLink
Log in

Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond

  • Inflammatory Bowel Disease (B Cohen, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Ulcerative colitis (UC) is a chronic disease with an increasing incidence. Recent guidelines emphasize treating toward objective targets, requiring the use of effective, steroid-sparing therapies. This review summarizes the safety and efficacy data of available therapies as well comparative effectiveness studies in order to help the reader make rational treatment decisions.

Recent Findings

Following the approval of tumor necrosis factor alpha antagonists, we have seen recent regulatory approval of several additional biologic and small molecule agents from several therapeutic classes (integrin antagonists, interleukin 12/23 antagonists, Janus kinase inhibitors, and sphingosine-1-phosphate receptor antagonists) for UC. Randomized, controlled trials, real-world analyses, and network meta-analyses have investigated the comparative safety and efficacy of these therapies in order to help clinicians better position these therapies in clinical practice.

Summary

Numerous agents are now approved for the treatment of UC. This evidence-based review will help the reader understand the important factors weighing into treatment decisions for patients with UC and enable patient education and discussion with a focus on a shared decision-making approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0.

    Article  Google Scholar 

  2. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–70. https://doi.org/10.1016/S0140-6736(16)32126-2.

    Article  Google Scholar 

  3. Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83. https://doi.org/10.1053/j.gastro.2020.12.031.

    Article  CAS  Google Scholar 

  4. Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology. 2015;149(1):238–45. https://doi.org/10.1053/j.gastro.2015.05.036.

    Article  Google Scholar 

  5. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43(1):29–32. https://doi.org/10.1136/gut.43.1.29.

    Article  CAS  Google Scholar 

  6. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9. https://doi.org/10.1056/NEJM198712243172603.

    Article  CAS  Google Scholar 

  7. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–6. https://doi.org/10.1002/ibd.20520.

    Article  Google Scholar 

  8. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.

    Article  Google Scholar 

  9. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92(10):1867–71.

    CAS  Google Scholar 

  10. Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13(8):1444-9.e1. https://doi.org/10.1016/j.cgh.2015.02.019.

    Article  CAS  Google Scholar 

  11. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974;4(5945):627–30. https://doi.org/10.1136/bmj.4.5945.627.

    Article  CAS  Google Scholar 

  12. Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018;155(4):1098-108.e9. https://doi.org/10.1053/j.gastro.2018.06.046.

    Article  CAS  Google Scholar 

  13. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. https://doi.org/10.1056/NEJMoa050516.

    Article  CAS  Google Scholar 

  14. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7. https://doi.org/10.1136/gut.2010.221127.

    Article  CAS  Google Scholar 

  15. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-65.e1-3. https://doi.org/10.1053/j.gastro.2011.10.032.

    Article  CAS  Google Scholar 

  16. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95. https://doi.org/10.1053/j.gastro.2013.05.048 (quiz e14-5).

    Article  CAS  Google Scholar 

  17. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96-109.e1. https://doi.org/10.1053/j.gastro.2013.06.010.

    Article  CAS  Google Scholar 

  18. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. https://doi.org/10.1056/NEJMoa1215734.

    Article  CAS  Google Scholar 

  19. Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229-39.e5. https://doi.org/10.1016/j.cgh.2016.08.044.

    Article  CAS  Google Scholar 

  20. Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14. https://doi.org/10.1056/NEJMoa1900750.

    Article  CAS  Google Scholar 

  21. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36. https://doi.org/10.1056/NEJMoa1606910.

    Article  CAS  Google Scholar 

  22. Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, et al. Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(8):1821-30.e3. https://doi.org/10.1016/j.cgh.2020.10.038.

    Article  CAS  Google Scholar 

  23. Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–28. https://doi.org/10.1016/S0140-6736(22)00581-5.

    Article  CAS  Google Scholar 

  24. Efficacy and safety of extended induction treatment with Upadacitinib 45 mg once daily followed by maintenance Upadacitinib 15 or 30 mg once daily in patients with moderately to severely active ulcerative colitis. Gastroenterol Hepatol (N Y). 2022;18(4 Suppl 1):3–4.

  25. Sandborn WJ, Feagan BG, D’Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280–91. https://doi.org/10.1056/NEJMoa2033617.

    Article  CAS  Google Scholar 

  26. Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550–61.

    Article  CAS  Google Scholar 

  27. Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: Results from the open-label extension of the OASIS study. J Crohns Colitis. 2021;15(6):950–9. https://doi.org/10.1093/ecco-jcc/jjab016.

    Article  Google Scholar 

  28. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur AJ, et al. 968a: Etrasimod 2mg once daily as treatment for moderately to severely active ulcerative colitis: Results from the phase 3 elevate UC 52 and elevate UC 12 trials. Gastroenterology. 2022;162(7):S-1395. https://doi.org/10.1016/S0016-5085(22)64063-0.

  29. Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, Törüner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–26. https://doi.org/10.1056/NEJMoa1905725.

    Article  CAS  Google Scholar 

  30. Peyrin-Biroulet L, Loftus EV, Colombel JF, Danese S, Rogers R, Bornstein JD, et al. Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: Results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY). Gastroenterology. 2021;161(4):1156-67.e3. https://doi.org/10.1053/j.gastro.2021.06.015.

    Article  CAS  Google Scholar 

  31. Danese S, Colombel JF, Lukas M, Gisbert JP, D’Haens G, Hayee B, et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(2):118–27. https://doi.org/10.1016/S2468-1253(21)00294-6.

    Article  Google Scholar 

  32. Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022;7(1):17–27. https://doi.org/10.1016/S2468-1253(21)00338-1.

    Article  Google Scholar 

  33. Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W. Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(7):1588-97.e3. https://doi.org/10.1016/j.cgh.2021.07.038.

    Article  CAS  Google Scholar 

  34. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179-91.e6. https://doi.org/10.1016/j.cgh.2020.01.008.

    Article  CAS  Google Scholar 

  35. Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454–65. https://doi.org/10.1111/apt.14449.

    Article  CAS  Google Scholar 

  36. Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021. https://doi.org/10.1136/gutjnl-2021-326390.

    Article  Google Scholar 

  37. Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–70. https://doi.org/10.1016/S2468-1253(21)00377-0.

    Article  Google Scholar 

  38. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345. https://doi.org/10.1038/s41395-018-0162-0.

    Article  CAS  Google Scholar 

  39. Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, et al. Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(1):126–35. https://doi.org/10.1016/j.cgh.2020.10.003.

    Article  CAS  Google Scholar 

  40. Meyer A, Fumery M, Peyrin-Biroulet L, Filippi J, Altwegg R, Bouhnik Y, et al. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scand J Gastroenterol. 2022;1–9. https://doi.org/10.1080/00365521.2022.2095668

  41. Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, et al. Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide dutch registry study. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2022.04.038.

    Article  Google Scholar 

  42. Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):460–6. https://doi.org/10.1111/apt.12417.

    Article  CAS  Google Scholar 

  43. Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160(4):1131–9. https://doi.org/10.1053/j.gastro.2020.11.038.

    Article  CAS  Google Scholar 

  44. Odufalu FD, Long M, Lin K, Mahadevan U, enrollment PIftCsaCFCCRArpftrcfp. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory Florence-Damilola Odufalu 1, Millie Long 2, Kirk Lin 3, Uma Mahadevan 4, PIANO Investigators from the Crohn’s and Colitis Collaborators. Gut. 2022;71(9):1766–1772. https://doi.org/10.1136/gutjnl-2021-325317.

  45. Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National health insurance database (EVASION). Am J Gastroenterol. 2018;113(11):1669–77. https://doi.org/10.1038/s41395-018-0176-7.

    Article  CAS  Google Scholar 

  46. Gisbert JP, Chaparro M. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review. Drugs. 2020;80(11):1085–100. https://doi.org/10.1007/s40265-020-01346-4.

    Article  CAS  Google Scholar 

  47. Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494–500. https://doi.org/10.1093/ibd/izy160.

    Article  Google Scholar 

  48. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990;336(8706):16–9. https://doi.org/10.1016/0140-6736(90)91521-b.

    Article  CAS  Google Scholar 

  49. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11. https://doi.org/10.1053/j.gastro.2005.03.003.

    Article  CAS  Google Scholar 

  50. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946–64. https://doi.org/10.1016/j.clinthera.2011.06.002.

    Article  CAS  Google Scholar 

  51. Berinstein JA, Sheehan JL, Dias M, Berinstein EM, Steiner CA, Johnson LA, et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021;19(10):2112-20.e1. https://doi.org/10.1016/j.cgh.2021.05.038.

    Article  CAS  Google Scholar 

  52. Hanzel J, Ma C, Casteele NV, Khanna R, Jairath V, Feagan BG. Vedolizumab and extraintestinal manifestations in inflammatory bowel disease. Drugs. 2021;81(3):333–47. https://doi.org/10.1007/s40265-020-01460-3.

    Article  CAS  Google Scholar 

  53. Kochar B, Orkaby AR, Ananthakrishnan AN, Ritchie CS. Frailty in inflammatory bowel diseases: an emerging concept. Therap Adv Gastroenterol. 2021;14:17562848211025474. https://doi.org/10.1177/17562848211025474.

    Article  CAS  Google Scholar 

  54. Wang JH, D'Arcy M, Barnes EL, Freedman ND, Engels EA, Song M. Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States. JNCI Cancer Spectr. 2021;6(1):pkab096. https://doi.org/10.1093/jncics/pkab096. eCollection 2022 Feb.

  55. Kochar B, Pate V, Kappelman MD, Long MD, Ananthakrishnan AN, Chan AT, et al. Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults. Clin Gastroenterol Hepatol. 2022;20(6):1299-305.e5. https://doi.org/10.1016/j.cgh.2021.08.047.

    Article  CAS  Google Scholar 

  56. Cheng D, Kochar B, Cai T, Ritchie CS, Ananthakrishnan AN. Comorbidity influences the comparative safety of biologic therapy in older adults with inflammatory bowel diseases. Am J Gastroenterol. 2022. https://doi.org/10.14309/ajg.0000000000001907.

    Article  Google Scholar 

  57. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26. https://doi.org/10.1056/NEJMoa2109927.

    Article  CAS  Google Scholar 

  58. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99(1):97–101. https://doi.org/10.1046/j.1572-0241.2003.04026.x.

    Article  Google Scholar 

  59. Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, et al. Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status. Clin Gastroenterol Hepatol. 2022;20(3):591-601.e8. https://doi.org/10.1016/j.cgh.2021.02.043.

    Article  CAS  Google Scholar 

  60. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035–47. https://doi.org/10.1111/j.1476-5381.2012.02061.x.

    Article  CAS  Google Scholar 

  61. Rowan C, Ungaro R, Mehandru S, Colombel JF. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opin Pharmacother. 2022;23(8):893–904. https://doi.org/10.1080/14656566.2022.2071605.

    Article  CAS  Google Scholar 

  62. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5(2):119–33. https://doi.org/10.1097/00054725-199905000-00008.

    Article  CAS  Google Scholar 

  63. Chupin A, Perduca V, Meyer A, Bellanger C, Carbonnel F, Dong C. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1289–97. https://doi.org/10.1111/apt.16050.

    Article  CAS  Google Scholar 

  64. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390-9.e1. https://doi.org/10.1053/j.gastro.2012.05.004.

    Article  Google Scholar 

  65. Sandborn WJ, Feagan BG, Danese S, O’Brien CD, Ott E, Marano C, et al. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies. Inflamm Bowel Dis. 2021;27(7):994–1007. https://doi.org/10.1093/ibd/izaa236.

    Article  Google Scholar 

  66. Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Hart A, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55(4):464–78. https://doi.org/10.1111/apt.16712.

    Article  CAS  Google Scholar 

  67. Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58–64. https://doi.org/10.1016/j.cgh.2015.07.037.

    Article  CAS  Google Scholar 

  68. Dulai PS, Singh S, Vande Casteele N, Meserve J, Winters A, Chablaney S, et al. Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(13):2952-61.e8. https://doi.org/10.1016/j.cgh.2020.02.010.

    Article  CAS  Google Scholar 

  69. Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15(10):1694–706. https://doi.org/10.1093/ecco-jcc/jjab058.

    Article  Google Scholar 

  70. Vermeire S, et al. S856 Efficacy of upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis. Am J Gastroenterol. 2021;pS399–S400. https://doi.org/10.14309/01.ajlg.0000776956.67866.43.

  71. Vermeire S, Colombel JF, Takeuchi K, Gao X, Panaccione R, Danese S, Dubinsky M, Schreiber S, Ilo D, Finney-Hayward T, Zhou W, Phillips C, Yao X, Zhou Q, Loftus E. DOP38 upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1. J Crohn’s Colitis. 2022;16(Supplement_1):i087–8. https://doi.org/10.1093/ecco-jcc/jjab232.077.

  72. Sands BE, Nguyen D, Pondel M, Silver M, Petersen AK, et al. S693 Impact of Prior biologic exposure on patient response to ozanimod for moderate-to-severe ulcerative colitis in the phase. Am J Gastroenterol. 2021;116:pS313–S314. https://doi.org/10.14309/01.ajg.0000776304.5261.bf

  73. Afsari S, Henry A, Comi G, Dubinsky MC, Mahadevan, U, Charles L, Janneke van der Woude C, Selmaj K. Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, ulcerative colitis, and Crohn’s disease. The Consortium of Multiple Sclerosis Centers Annual Meeting. 2021. https://2021abstracts.cmscscholar.org/2021/10/25/pregnancy-outcomes-in-the-ozanimod-clinical-development-program-in-relapsing-multiple-sclerosis-ulcerative-colitis-and-crohn%C2%92s-disease/. Accessed 22 Jul 2022.

  74. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and. Accessed 22 Jul 2022.

  75. Package Insert for Remicade (infliximab; Janssen): www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf. Accessed 22 Jul 2022.

  76. Package Insert for Humira (adalimumab; Abbvie): www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf. Accessed 22 Jul 2022.

  77. Package Insert for Simponi (golimumab; Janssen): www.accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0064lbl.pdf. Accessed 22 Jul 2022.

  78. Axelrad J, Colombel J-F, Scherl E, Lukin D, Chang S, Chen LA, Kwah J, Swaminath A, Sultan K, Lawlor G, Villagra C, Yue J, Sharpless V, Itzkowitz S. Updates from the SAPPHIRE Registry: Safety of Immunosuppression in a prospective cohort of inflammatory bowel disease patinets with a history of cancer. Gastroenterol. 162.7 2022;S-959.

Download references

Author information

Authors and Affiliations

  1. Jill Roberts Center for Inflammatory Bowel Disease, New York Presbyterian-Weill Cornell Medicine, New York, NY, USA

    Amneet Hans & Dana J. Lukin

  2. Division of Gastroenterology and Hepatology, Centre Hospitalier de L’Université de Montréal (CHUM), University of Montreal, Quebec, Montreal, Canada

    Robert Battat

Authors
  1. Amneet Hans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Battat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dana J. Lukin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dana J. Lukin.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclosures

AH: no disclosures.

RB: Consulting/Speaking Fees: Bristol Myers Squibb, Prometheus Laboratories.

DJL: Consulting/Speaking Fees: Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Prometheus Laboratories, Palatin Technologies, Pfizer. Grant Support: Abbvie, Janssen, Takeda.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Inflammatory Bowel Disease.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hans, A., Battat, R. & Lukin, D.J. Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Curr Gastroenterol Rep 24, 157–170 (2022). https://doi.org/10.1007/s11894-022-00853-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-022-00853-6

Keywords

Search

Navigation